Boston Scientific’s performance was also in line with its peers, including Medtronic, Abbott, and Intuitive Surgical, all down between 8% and 12% over the last month. Despite the ongoing supply chain disruption, the company posted upbeat Q1 results and raised its full-year outlook. The S&P500 has now entered the bear market territory with rising concerns of slowing economic growth given the high inflation, Fed action, and supply chain disruptions.